Table 3. Clinicopathological features of the 114 donors of the prostate tissues used in the TMA study.
| Characteristics | Patients | ||
|---|---|---|---|
| n | (%) | ||
| Age | ≤65 years | 45 | 39.5 |
| >65 years | 69 | 60.5 | |
| Normal | 8 | 7.0 | |
| NAT | 12 | 10.5 | |
| Histology | Adenocarcinoma | 92 | 80.7 |
| Transitional cell carcinoma | 2 | 1.8 | |
| Grade | 1 | 9 | 7.9 |
| 2 | 37 | 32.5 | |
| 2–3 | 3 | 2.6 | |
| 3 | 30 | 26.3 | |
| 4 | 10 | 8.8 | |
| Not determined | 5 | 4.4 | |
| Gleason grade | 1 | 9 | 7.9 |
| 2 | 7 | 6.1 | |
| 3 | 25 | 21.9 | |
| 4 | 23 | 20.2 | |
| 5 | 26 | 22.8 | |
| Not determined | 2 | 1.8 | |
| Gleason score | 1+1 | 4 | 3.5 |
| 1+2 | 1 | 0.9 | |
| 1+3 | 1 | 0.9 | |
| 1+4 | 1 | 0.9 | |
| 2+2 | 8 | 7.0 | |
| 2+3 | 11 | 9.6 | |
| 2+4 | 1 | 0.9 | |
| 2+5 | 1 | 0.9 | |
| 3+2 | 1 | 0.9 | |
| 3+3 | 14 | 12.3 | |
| 3+4 | 6 | 5.3 | |
| 3+5 | 3 | 2.6 | |
| 4+2 | 1 | 0.9 | |
| 4+3 | 5 | 4.4 | |
| 4+4 | 12 | 10.5 | |
| 4+5 | 3 | 2.6 | |
| 5+3 | 2 | 1.8 | |
| 5+4 | 4 | 3.5 | |
| 5+5 | 13 | 11.4 | |